Results 1 - 10 of 804
- As top court invalidates some gene patents, biotech has moved on
- ... And Roche Holding AG's Genentech, as well as Novo Nordisk, hold patents on the DNA they have constructed to make bacteria churn out human hormones or vaccine ...
- Swiss stocks - Factors to watch on May 21
- ... For more, click on. ROCHE. * Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug ...
- European Factors to Watch-Shares seen retreating from 5-yr high
- ... ROCHE Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer ...
- Regeneron settles all pending litigation with Roche's Genentech
- May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and ...
- DEALTALK-Novartis' Vasella exit opens door to Roche stake sale
- ... is edging closer to its target for a net debt to assets ratio of 0-15 percent, after paying down debt from its 2009 acquisition of Californian biotech Genentech ...
- FDA approves Roche diagnostic for gene mutation in lung cancer
- ... their initial treatment to help them live longer without their disease worsening," Hal Barron, chief medical officer of Roche Holding Ag's Genentech unit, said ...
- FEATURE-Fast climbing biotech Regeneron still has room to grow
- ... "We would like to be one of the next generational businesses in our industry, and the best examples of that would be Merck and Genentech," Chief Executive ...
- Roche says no plans to change holding in Japan's Chugai
- ... There has been speculation that Roche might look to take complete ownership of Chugai, as it did with the buyout of US biotech group Genentech in 2009. ...
- CORRECTED-Roche immune therapy cancer drug shows promise in early ...
- ... researchers said on Tuesday. The drug, called MPDL3280A, was discovered and is being developed by Roche's Genentech unit. The Phase 1 ...
- Roche immune therapy cancer drug shows promise in early study
- ... researchers said on Tuesday. The drug, called MPDL3280A, was discovered and is being developed by Roche's Genentech unit. The Phase 1 ...
Video Results
Pictures Results
Results 1 - 3 of 3
View Picture
Bill Burns, CEO Division of Roche Pharmaceuticals, speaks during ...
View Picture
A general view shows the headquarters of Swiss drugmaker Roche ...
View Picture
The logo of Swiss pharmaceutical company Roche's is seen during ...
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
